Recro Pharma Inc (REPH) 9.46 $REPH
Recro Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 16, 7:59AM CDT
Recro Pharma, Inc. ("Recro" or the "Company"
(Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced the pricing of an underwritten public offering of 1,986,666 shares of its common stock at a price of $7.50 per share.
REPH: 9.46 (unch)
Recro Pharma Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 6:00AM CDT
Announced Positive Top-line Results from Pivotal Phase III Trial of IV Meloxicam Following Bunionectomy Surgery
REPH: 9.46 (unch)
Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on Thursday, June 9, 2016 at 11:00 am EDT. The conference is being held at the Grand Hyatt in New York City.
REPH: 9.46 (unch)
Recro Pharma reports 1Q loss
Automated Insights - Thu May 12, 8:16AM CDT
MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Thursday reported a loss of $6.5 million in its first quarter.
REPH: 9.46 (unch)
Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Thu May 12, 8:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious acute pain, today announced a poster presentation at the American Pain Society's 35 Annual Scientific Meeting, taking place May 11-14, 2016, in Austin, TX. The poster presentation highlights data from a clinical trial evaluating the efficacy and safety of intravenous (IV) meloxicam (N1539), in subjects with moderate to severe pain following open abdominal hysterectomy.
REPH: 9.46 (unch)
Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.77 (+0.03), REPH: 9.46 (unch)
Recro Pharma Reports Year End 2015 Financial Results
GlobeNewswire - Thu Mar 24, 7:20AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain, today reported financial results for the year ended December 31, 2015.
REPH: 9.46 (unch)
Recro Pharma to Present at NobleCon12 Investor Conference
GlobeNewswire - Thu Jan 14, 12:19PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at Noble Financial Capital Markets' 12th Annual Investor Conference (NobleCon12) on Tuesday, January 19, 2016 at 4:00 pm EST. The conference is being held at Club Med in Sandpiper Bay, Florida.
REPH: 9.46 (unch)
Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 3.09 (+0.04), KMPH: 4.64 (+0.20), NKTR: 18.45 (+0.34), INSY: 14.63 (+0.27), AVXL: 3.05 (+0.02), PCRX: 39.04 (-1.33), REPH: 9.46 (unch), PTIE: 2.27 (-0.05)
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
AMZN: 772.44 (+1.82), EFOI: 3.90 (+0.03), EGRX: 60.34 (+1.32), REPH: 9.46 (unch), NVDA: 62.53 (-0.62)
Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
GlobeNewswire - Wed Jan 06, 6:00AM CST
IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported
REPH: 9.46 (unch)
Buffett Fans Take Note: 5 Stocks That Crushed Berkshire Hathaway in 2015
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:23PM CST
There is no doubt that Berkshire Hathaway Inc. (BRK.
is a stock that most investors want in their portfolio.
AMZN: 772.44 (+1.82), EFOI: 3.90 (+0.03), AXP: 65.19 (+0.33), IBM: 159.55 (+0.01), EGRX: 60.34 (+1.32), BRK.B: 150.72 (+0.37), REPH: 9.46 (unch), NVDA: 62.53 (-0.62)
5 Small Cap ETFs & Stocks that Beat Russell 2000 in 2015
Sweta Killa - Zacks Investment Research - Mon Jan 04, 9:59AM CST
These ETFs and stocks have shown strong resilience to the sharp downturn in the small cap space and the trend is likely to continue, making these lucrative picks for 2016.
PSCH: 74.23 (+1.05), NPTN: 15.68 (+0.43), LPTH: 1.94 (+0.04), REPH: 9.46 (unch), PSCT: 62.77 (+0.78), PSCU: 45.67 (+0.54)
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
EFOI: 3.90 (+0.03), LPTH: 1.94 (+0.04), EGRX: 60.34 (+1.32), REPH: 9.46 (unch), HQCL: 12.01 (+0.21)
Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
GlobeNewswire - Wed Dec 02, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment of Stewart McCallum, M.D., as Chief Medical Officer.
REPH: 9.46 (unch)
Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 2015 Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:10 am EST. The conference is being held at the Lotte New York Palace Hotel in New York City.
REPH: 9.46 (unch)
Recro Pharma Reports Third Quarter 2015 Financial Results
GlobeNewswire - Fri Nov 13, 5:59AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today reported financial results for the third quarter ended September 30, 2015.
REPH: 9.46 (unch)
Recro Pharma to Participate in Upcoming Investor Conferences
GlobeNewswire - Thu Nov 12, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in the following upcoming investor conferences:
REPH: 9.46 (unch)
Recro Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 16, 7:59AM CDT
Recro Pharma, Inc. ("Recro" or the "Company"
(Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced the pricing of an underwritten public offering of 1,986,666 shares of its common stock at a price of $7.50 per share. REPH: 9.46 (unch)
Recro Pharma Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 6:00AM CDT
Announced Positive Top-line Results from Pivotal Phase III Trial of IV Meloxicam Following Bunionectomy Surgery
REPH: 9.46 (unch)
Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on Thursday, June 9, 2016 at 11:00 am EDT. The conference is being held at the Grand Hyatt in New York City.
REPH: 9.46 (unch)
Recro Pharma reports 1Q loss
Automated Insights - Thu May 12, 8:16AM CDT
MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Thursday reported a loss of $6.5 million in its first quarter.
REPH: 9.46 (unch)
Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Thu May 12, 8:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious acute pain, today announced a poster presentation at the American Pain Society's 35 Annual Scientific Meeting, taking place May 11-14, 2016, in Austin, TX. The poster presentation highlights data from a clinical trial evaluating the efficacy and safety of intravenous (IV) meloxicam (N1539), in subjects with moderate to severe pain following open abdominal hysterectomy.
REPH: 9.46 (unch)
Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.77 (+0.03), REPH: 9.46 (unch)
Recro Pharma Reports Year End 2015 Financial Results
GlobeNewswire - Thu Mar 24, 7:20AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain, today reported financial results for the year ended December 31, 2015.
REPH: 9.46 (unch)
Recro Pharma to Present at NobleCon12 Investor Conference
GlobeNewswire - Thu Jan 14, 12:19PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at Noble Financial Capital Markets' 12th Annual Investor Conference (NobleCon12) on Tuesday, January 19, 2016 at 4:00 pm EST. The conference is being held at Club Med in Sandpiper Bay, Florida.
REPH: 9.46 (unch)
Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 3.09 (+0.04), KMPH: 4.64 (+0.20), NKTR: 18.45 (+0.34), INSY: 14.63 (+0.27), AVXL: 3.05 (+0.02), PCRX: 39.04 (-1.33), REPH: 9.46 (unch), PTIE: 2.27 (-0.05)
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
AMZN: 772.44 (+1.82), EFOI: 3.90 (+0.03), EGRX: 60.34 (+1.32), REPH: 9.46 (unch), NVDA: 62.53 (-0.62)
Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
GlobeNewswire - Wed Jan 06, 6:00AM CST
IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported
REPH: 9.46 (unch)
Buffett Fans Take Note: 5 Stocks That Crushed Berkshire Hathaway in 2015
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:23PM CST
There is no doubt that Berkshire Hathaway Inc. (BRK.
is a stock that most investors want in their portfolio. AMZN: 772.44 (+1.82), EFOI: 3.90 (+0.03), AXP: 65.19 (+0.33), IBM: 159.55 (+0.01), EGRX: 60.34 (+1.32), BRK.B: 150.72 (+0.37), REPH: 9.46 (unch), NVDA: 62.53 (-0.62)
5 Small Cap ETFs & Stocks that Beat Russell 2000 in 2015
Sweta Killa - Zacks Investment Research - Mon Jan 04, 9:59AM CST
These ETFs and stocks have shown strong resilience to the sharp downturn in the small cap space and the trend is likely to continue, making these lucrative picks for 2016.
PSCH: 74.23 (+1.05), NPTN: 15.68 (+0.43), LPTH: 1.94 (+0.04), REPH: 9.46 (unch), PSCT: 62.77 (+0.78), PSCU: 45.67 (+0.54)
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
EFOI: 3.90 (+0.03), LPTH: 1.94 (+0.04), EGRX: 60.34 (+1.32), REPH: 9.46 (unch), HQCL: 12.01 (+0.21)
Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
GlobeNewswire - Wed Dec 02, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment of Stewart McCallum, M.D., as Chief Medical Officer.
REPH: 9.46 (unch)
Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 2015 Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:10 am EST. The conference is being held at the Lotte New York Palace Hotel in New York City.
REPH: 9.46 (unch)
Recro Pharma Reports Third Quarter 2015 Financial Results
GlobeNewswire - Fri Nov 13, 5:59AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today reported financial results for the third quarter ended September 30, 2015.
REPH: 9.46 (unch)
Recro Pharma to Participate in Upcoming Investor Conferences
GlobeNewswire - Thu Nov 12, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in the following upcoming investor conferences:
REPH: 9.46 (unch)
